Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

38.57 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk ↗

February 24, 2025

Via The Motley Fool

Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday ↗

February 19, 2025

Via Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 13, 2025

Via Benzinga

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today ↗

February 11, 2025

Via Benzinga

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today ↗

February 10, 2025

Via The Motley Fool

2 Stocks to Buy With Less Than $40 ↗

February 10, 2025

Via The Motley Fool

2 Stocks That Could Soar Again in 2025 ↗

February 08, 2025

Via The Motley Fool

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now ↗

February 10, 2025

Via The Motley Fool

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip? ↗

February 08, 2025

Via The Motley Fool

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year ↗

February 07, 2025

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.

Via Stocktwits

We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗

February 07, 2025

Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...

Via Stocktwits

Market Movers: $ASTS Surges Again, $PBI Gears Up For Earnings! ↗

February 06, 2025

Pre-Market Briefing: Feb 6 – Top trade setups using our 4-pillar strategy! $ASTS leads the way, $PBI gears up for earnings, and $PTON & $APPS ride post-earnings momentum.

Via Talk Markets

Topics Stocks / Equities

Has the Bubble Burst for Viking Therapeutics Stock? ↗

February 06, 2025

Via The Motley Fool

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

(VKTX) - Analyzing Viking Therapeutics's Short Interest ↗

January 28, 2025

Via Benzinga

This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025? ↗

January 22, 2025

Via The Motley Fool

Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. ↗

February 05, 2025

Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates.

Via Investor's Business Daily

Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates ↗

February 05, 2025

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the details from the report.

Via Benzinga

This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy? ↗

February 02, 2025

Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics.

Via The Motley Fool

Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive' ↗

January 29, 2025

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗

January 16, 2025

Via Benzinga

Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results ↗

January 24, 2025

The Danish drug giant reported a 22% weight loss over 36 weeks.

Via Investor's Business Daily

Top 3 Health Care Stocks That Could Blast Off This Quarter ↗

January 22, 2025

Via Benzinga

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today ↗

January 17, 2025

Via The Motley Fool

We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks ↗

January 15, 2025

Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover.

Via Stocktwits

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday ↗

January 14, 2025

Via The Motley Fool

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

3 Mid-Cap Stocks That Could Take Off in 2025 ↗

January 09, 2025

Via The Motley Fool

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗

January 06, 2025

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.